PubRank

Fabio Fulfaro

Author PubWeight™ 25.31‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res 2007 3.22
2 Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003 1.65
3 Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev 2010 1.15
4 Management of painful bone metastases. Curr Opin Oncol 2007 1.12
5 Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 2008 1.04
6 Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res 2008 0.93
7 Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol 2008 0.92
8 The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology 2010 0.89
9 Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis 2010 0.87
10 Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002 0.87
11 Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage 2007 0.86
12 Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer 2009 0.85
13 Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain 2010 0.84
14 Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother 2009 0.83
15 Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets 2010 0.82
16 Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006 0.82
17 Minor hepatic resection using heat coagulative necrosis. Am Surg 2009 0.81
18 Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin 2012 0.81
19 Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. Anticancer Res 2013 0.80
20 Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother Pharmacol 2005 0.80
21 Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home. Support Care Cancer 2003 0.80
22 Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1). Thromb Res 2011 0.80
23 TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. J Cell Physiol 2006 0.79
24 Pain mechanisms involved and outcome in advanced cancer patients with possible indications for celiac plexus block and superior hypogastric plexus block. Tumori 2002 0.79
25 A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007 0.79
26 Clinical presentation and treatment of gastrointestinal stromal tumors. Tumori 2006 0.79
27 Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Anticancer Res 2006 0.77
28 A case of squamocellular uterine cervix carcinoma metastatic to the skin with enterocutaneous fistula. Tumori 2006 0.75
29 [Oral complications in patients with head and neck cancer after radio-chemotherapy. Mucositis and xerostomia]. Recenti Prog Med 2007 0.75